A non-surgical COMBO-therapy approach for locally advanced unresectable pancreatic adenocarcinoma: preliminary results of a prospective study.
Adenocarcinoma
/ diagnostic imaging
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Chemoradiotherapy
/ methods
Diagnostic Imaging
/ methods
Humans
Pancreas
/ diagnostic imaging
Pancreatic Neoplasms
/ diagnostic imaging
Prospective Studies
Radiosurgery
/ methods
Treatment Outcome
Pancreatic Neoplasms
Chemotherapy
Pancreatic cancer
Radiotherapy
Stereotactic radiotherapy
Journal
La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
02
10
2021
accepted:
21
12
2021
pubmed:
17
1
2022
medline:
22
2
2022
entrez:
16
1
2022
Statut:
ppublish
Résumé
In this short report we present a series of thirteen patients with locally advanced, unresectable, pancreatic cancer treated with a COMBO-Therapy consisting of: STEP-1: induction chemotherapy; STEP-2: concomitant chemoradiotherapy; STEP-3: stereotactic body radiotherapy boost. After four weeks from the end of each step all patients had a re-staging and a surgical re-evaluation. All patients completed STEP-1 and STEP-2. STEP-3 has been successfully delivered to 8/13 patients with a median dose of 12 Gy (range 10-21 Gy) in 1-3 fractions. The median LC was 20 months (range 10-32) with a 2-year LC of 72.9%, and none of the patients developed G3 acute or late toxicities. The median OS was 21.5 months (range 12-34), and the 2-year OS was 53.9%; the median PFS was 17.5 months (range 10-27). Our non-surgical COMBO-Therapy has demonstrated a feasible profile with good tolerance. Further prospective protocols are needed to confirm our preliminary results.
Identifiants
pubmed: 35034325
doi: 10.1007/s11547-021-01441-w
pii: 10.1007/s11547-021-01441-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
214-219Informations de copyright
© 2022. Italian Society of Medical Radiology.
Références
Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30. https://doi.org/10.3322/caac.21166
doi: 10.3322/caac.21166
pubmed: 23335087
Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30. https://doi.org/10.3322/caac.21332
doi: 10.3322/caac.21332
pubmed: 26742998
Chin V, Nagrial A, Sjoquist K, et al (2018) Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database Syst. Rev. 2018
Hidalgo M (2010) Pancreatic Cancer. N Engl J Med 362:1605–1617. https://doi.org/10.1056/NEJMra0901557
doi: 10.1056/NEJMra0901557
pubmed: 20427809
Suker M, Beumer BR, Sadot E et al (2016) FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 17:801–810. https://doi.org/10.1016/S1470-2045(16)00172-8
doi: 10.1016/S1470-2045(16)00172-8
pubmed: 27160474
pmcid: 5527756
Von Hoff DD, Ervin T, Arena FP et al (2013) Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med 369:1691–1703. https://doi.org/10.1056/nejmoa1304369
doi: 10.1056/nejmoa1304369
Hammel P, Huguet F, Van Laethem JL et al (2016) Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib the LAP07 randomized clinical trial. JAMA J Am Med Assoc 315:1844–1853. https://doi.org/10.1001/jama.2016.4324
doi: 10.1001/jama.2016.4324
Landau E, Kalnicki S (2018) The Evolving Role of Radiation in Pancreatic Cancer. Surg Clin North Am 98:113–125
doi: 10.1016/j.suc.2017.09.008
Huguet F, Girard N, Séblain-El Guerche C et al (2009) Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 27:2269–2277
doi: 10.1200/JCO.2008.19.7921
Chung SY, Chang JS, Lee BM et al (2017) Dose escalation in locally advanced pancreatic cancer patients receiving chemoradiotherapy. Radiother Oncol 123:438–445. https://doi.org/10.1016/j.radonc.2017.04.010
doi: 10.1016/j.radonc.2017.04.010
pubmed: 28464997
Ben-Josef E, Schipper M, Francis IR et al (2012) A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 84:1166–1171. https://doi.org/10.1016/j.ijrobp.2012.02.051
doi: 10.1016/j.ijrobp.2012.02.051
pubmed: 22543215
pmcid: 3421048
Oba A, Ho F, Bao QR, et al (2020) Neoadjuvant Treatment in Pancreatic Cancer. Front. Oncol. 10
Iatì G, Parisi S, Santacaterina A et al (2020) simultaneous integrated boost radiotherapy in unresectable stage IV (M0) head and neck squamous cell cancer patients: daily clinical practice. Reports Pract Oncol Radiother 25:399–404. https://doi.org/10.1016/j.rpor.2020.04.006
doi: 10.1016/j.rpor.2020.04.006
Ferini G, Caccola A, Parisi S et al (2021) Curative Radiotherapy in Elderly Patients With Muscle Invasive Bladder Cancer: The Prognostic Role of Sarcopenia. In Vivo 35:571–578. https://doi.org/10.21873/INVIVO.12293
Koong AC, Le QT, Ho A et al (2004) Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 58:1017–1021. https://doi.org/10.1016/j.ijrobp.2003.11.004
doi: 10.1016/j.ijrobp.2003.11.004
pubmed: 15001240
Cacciola A, Parisi S, Tamburella C et al (2020) Stereotactic body radiation therapy and radiofrequency ablation for the treatment of liver metastases: How and when? Reports Pract Oncol Radiother J Gt Cancer Cent Pozn Polish Soc Radiat Oncol 25:299–306. https://doi.org/10.1016/J.RPOR.2020.02.010
doi: 10.1016/J.RPOR.2020.02.010
Pontoriero A, Iatì G, Cacciola A et al (2020) Stereotactic body radiation therapy with simultaneous integrated boost in patients with spinal metastases. Technol Cancer Res Treat 19:153303. https://doi.org/10.1177/1533033820904447
doi: 10.1177/1533033820904447
Ferini G, Valenti V, Tripoli A et al (2021) Lattice or oxygen-guided radiotherapy: What if they converge? possible future directions in the era of immunotherapy. Cancers (Basel) 13:3290. https://doi.org/10.3390/CANCERS13133290
doi: 10.3390/CANCERS13133290
Chuong MD, Springett GM, Freilich JM et al (2013) Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys 86:516–522. https://doi.org/10.1016/j.ijrobp.2013.02.022
doi: 10.1016/j.ijrobp.2013.02.022
pubmed: 23562768
Schellenberg D, Kim J, Christman-Skieller C et al (2011) Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 81:181–188. https://doi.org/10.1016/j.ijrobp.2010.05.006
doi: 10.1016/j.ijrobp.2010.05.006
pubmed: 21549517
Mattiucci GC, Boldrini L, Nardangeli A et al (2021) Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients. J Cancer Res Clin Oncol 147:661–667. https://doi.org/10.1007/s00432-020-03411-7
doi: 10.1007/s00432-020-03411-7
pubmed: 33001271
Bruynzeel AME, Lagerwaard FJ (2019) The role of biological dose-escalation for pancreatic cancer. Clin Transl Radiat Oncol 18:128–130
doi: 10.1016/j.ctro.2019.04.020
Caravatta L, Sallustio G, Pacelli F et al (2012) Clinical target volume delineation including elective nodal irradiation in preoperative and definitive radiotherapy of pancreatic cancer. Radiat Oncol 7:1–10. https://doi.org/10.1186/1748-717X-7-86
doi: 10.1186/1748-717X-7-86
Kaplan EL, Meier P (1958) Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc 53:457–481. https://doi.org/10.1080/01621459.1958.10501452
doi: 10.1080/01621459.1958.10501452
Kunzmann V, Siveke JT, Algül H et al (2021) Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 6:128–138. https://doi.org/10.1016/S2468-1253(20)30330-7
doi: 10.1016/S2468-1253(20)30330-7
pubmed: 33338442
Mahadevan A, Miksad R, Goldstein M et al (2011) Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys 81:e615–e622. https://doi.org/10.1016/j.ijrobp.2011.04.045
doi: 10.1016/j.ijrobp.2011.04.045
pubmed: 21658854
Kelly P, Das P, Pinnix CC et al (2013) Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 85:e143–e149. https://doi.org/10.1016/j.ijrobp.2012.09.035
doi: 10.1016/j.ijrobp.2012.09.035
pubmed: 23200173
Mahadevan A, Jain S, Goldstein M et al (2010) Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 78:735–742. https://doi.org/10.1016/j.ijrobp.2009.08.046
doi: 10.1016/j.ijrobp.2009.08.046
pubmed: 20171803
Koong AC, Christofferson E, Le QT et al (2005) Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 63:320–323. https://doi.org/10.1016/j.ijrobp.2005.07.002
doi: 10.1016/j.ijrobp.2005.07.002
pubmed: 16168826
Seo YS, Kim MS, Yoo SY et al (2009) Stereotactic body radiation therapy boost in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 75:1456–1461. https://doi.org/10.1016/j.ijrobp.2009.01.042
doi: 10.1016/j.ijrobp.2009.01.042
pubmed: 19783379